{"source_content":"请务必阅读正文之后的免责条款部分1/3[Table_Main]公司研究|医疗保健|制药、生物科技与生命科学证券研究报告爱美客(300896)公司点评报告2020年10月27日[Table_Title]医美旺季来袭，业绩高质提升——爱美客2020年三季报点评[Table_Summary]事件：2020年10月27日，公司公告2020年三季报：公司前三季度实现营收4.64亿元，同比增加17.40%，归母净利润2.90亿元，同比增加31.83%，扣非后归母净利润2.80亿元，同比增加29.91%。国元观点：疫情后医美旺季来袭，Q3单季度增长亮眼公司Q3单季度实现营收2.23亿元，同比增长43.18%，实现归母净利润1.43亿元，同比增长55.97%，相比于上半年收入端0.72%的增速和归母净利润端14.59%的增速，Q3单季度提速加快。随着疫情消散，医美的需求正在快速恢复，有望迎来小爆发，叠加下半年为各大医美机构的店庆、周年庆活动的高峰期，服务机构积极进行产品和项目推广，公司的嗨体是目前唯一获批用于颈纹填充的产品，市场需求旺盛，正处于快速放量期，有望继续保持高速增长；其余数款玻尿酸系列产品满足中高端需求，价格体系维护良好；在研的童颜针、肉毒素有望陆续获批，继续助推业绩。费用控制有效，净利率提升明显前三季度销售毛利率达69.41%（+5.73pct），公司费用端控制出色，销售费用率9.05%（-2.61pct），管理费用率5.74%（-3.28pct），研发费用率7.12%（-0.69pct），盈利能力得到进一步提高，公司前三季度净利率达62.53%，同比提升6.84pct，环比H1提升，公司净利率稳步提升，经营性现金流2.59亿元，同比提升20.47%，环比H1提升125.22%，改善明显，公司经营效率提升。投资建议与盈利预测公司专注医美板块，产品定位清晰、差异化竞争，产品渗透率、渠道覆盖力仍有较大提升空间。随着公司嗨体不断放量、新品落地以及经营效率提高，我们预计公司20-22年营业收入为7.16亿元、9.64亿元和13.39亿元，归母净利润为4.58亿元、6.30亿元和8.49亿元，对应EPS分别为3.81元/股、5.24元/股、7.07元/股，对应PE129/94/70，考虑公司医美产品线齐全且产品具有市场差异化趋势，给予“增持”评级。风险提示市场竞争加剧，新品推广不及预期，研发不及预期等。[Table_Finance]附表：盈利预测财务数据和估值201820192020E2021E2022E营业收入(百万元)321.01557.72716.18964.411339.00收入同比（%）44.2873.7428.4134.6638.84归母净利润(百万元)122.85305.52457.99630.09849.23归母净利润同比(%)49.47148.6849.9137.5834.78ROE（%）0.310.460.100.120.14每股收益（元）1.022.543.815.247.07市盈率(P/E)479.49192.81128.6293.4969.37资料来源：Wind,国元证券研究中心[Table_Invest]增持|首次评级[Table_TargetPrice]当前价：490.08元/股[Table_Base]基本数据52周最高/最低价（元）：490.08/330.24A股流通股（百万股）：26.01A股总股本（百万股）：120.20流通市值（百万元）：11832.91总市值（百万元）：54691.00[Table_PicQuote]过去一年股价走势资料来源：Wind[Table_DocReport]相关研究报告[Table_Author]报告作者分析师常启辉执业证书编号S0020517090001电话021-51097188-1936邮箱changqihui@gyzq.com.cn联系人刘慧敏电话021-51097188邮箱liuhuimin@gyzq.com.cn联系人刘巧电话021-51097188邮箱liuqiao@gyzq.com.cn-3%6%15%25%34%9/2810/510/1210/1910/26爱美客沪深300国元持仓信息：持仓超过1%需披露，不超过1%则无需披露请务必阅读正文之后的免责条款部分2/3[Table_FinanceDetail]财务预测表资产负债表单位:百万元利润表单位:百万元会计年度201820192020E2021E2022E会计年度201820192020E2021E2022E流动资产296.26564.704392.625015.835852.44营业收入321.01557.72716.18964.411339.00现金265.55505.614331.574935.805749.74营业成本34.2241.1058.3577.8097.09应收账款9.1214.7417.9024.1133.48营业税金及附加6.163.544.666.278.70其他应收款1.962.303.584.826.70营业费用62.4177.1796.68139.84187.46预付账款3.334.575.847.789.71管理费用44.4448.0975.20110.91160.68存货12.9723.2928.7438.3247.82研发费用33.6848.5665.00100.00120.00其他流动资产3.3314.195.005.005.00财务费用-1.72-1.71-100.13-191.83-221.19非流动资产167.35178.95167.58161.82156.07资产减值损失-1.07-0.020.000.000.00长期投资0.000.000.000.000.00公允价值变动收益0.000.000.000.000.00固定资产138.35150.64144.89139.14133.38投资净收益0.756.975.005.005.00无形资产8.9110.6610.6610.6610.66营业利润143.27350.21523.42728.43993.26其他非流动资产20.0917.6412.0212.0212.02营业外收入0.000.680.000.000.00资产总计463.61743.654560.205177.656008.51营业外支出0.080.100.000.000.00流动负债44.6867.2445.9151.3157.95利润总额143.19350.79523.42728.43993.26短期借款0.000.000.000.000.00所得税27.0652.8278.51116.55168.85应付账款20.637.438.7511.6714.56净利润116.13297.97444.91611.88824.40其他流动负债24.0559.8137.1639.6443.39少数股东损益-6.73-7.55-13.09-18.21-24.83非流动负债14.1813.7013.5113.6813.49归属母公司净利润122.85305.52457.99630.09849.23长期借款0.000.000.000.000.00EBITDA149.65358.57429.04542.35777.82其他非流动负债14.1813.7013.5113.6813.49EPS（元）1.373.393.815.247.07负债合计58.8780.9559.4264.9971.45少数股东权益6.333.77-9.32-27.53-52.36主要财务比率股本90.0090.00120.20120.20120.20会计年度201820192020E2021E2022E资本公积139.69139.693502.663502.663502.66成长能力留存收益168.72429.24887.231517.322366.56营业收入(%)44.2873.7428.4134.6638.84归属母公司股东权益398.41658.934510.095140.185989.42营业利润(%)52.90144.4549.4639.1736.36负债和股东权益463.61743.654560.205177.656008.51归属母公司净利润(%)49.47148.6849.9137.5834.78获利能力现金流量表单位:百万元毛利率(%)89.3492.6391.8591.9392.75会计年度201820192020E2021E2022E净利率(%)38.2754.7863.9565.3363.42经营活动现金流135.50309.72327.66407.40587.75ROE(%)30.8446.3710.1512.2614.18净利润116.13297.97444.91611.88824.40ROIC(%)85.31193.23210.73252.43339.35折旧摊销8.1110.065.755.755.75偿债能力财务费用-1.72-1.71-100.13-191.83-221.19资产负债率(%)12.7010.881.301.261.19投资损失-0.75-6.97-5.00-5.00-5.00净负债比率(%)0.000.000.000.000.00营运资金变动6.026.82-23.32-13.72-16.17流动比率663.03839.799566.999774.7410098.49其他经营现金流7.703.545.450.32-0.04速动比率634.01804.539503.459698.9310014.73投资活动现金流-38.41-25.625.005.005.00营运能力资本支出39.1632.600.000.000.00总资产周转率74.6592.3927.0119.8123.94长期投资0.000.000.000.000.00应收账款周转率4750.934676.354388.134590.824650.50其他投资现金流0.756.975.005.005.00应付账款周转率140.04292.95721.15761.90740.20筹资活动现金流-45.89-44.033493.30191.83221.19每股指标（元）短期借款0.000.000.000.000.00每股收益(最新摊薄)102.21254.18381.03524.20706.52长期借款-5.510.000.000.000.00每股经营现金流(最新摊薄)112.73257.67272.60338.93488.98普通股增加0.000.0030.200.000.00每股净资产(最新摊薄)331.46548.203752.164276.364982.88资本公积增加0.000.003362.970.000.00估值比率其他筹资现金流-40.38-44.03100.13191.83221.19P/E47948.9719281.1112862.119349.066936.55现金净增加额51.20240.063825.96604.23813.94P/B14785.548939.841306.131146.02983.53EV/EBITDA39016.5716284.3313609.3210766.167506.89","data":[{"id":"1","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"公司前三季度实现营收4.64亿元","content_offset":["171","187"],"indicators":[{"indicator_name":"营业收入","indicator_value":["4.64亿元","181","187"],"indicator_element":{"公司":["爱美客","115","118"],"时间":["前三季度","173","177"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"同比增加17.40%","content_offset":["188","198"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["17.40%","192","198"],"indicator_element":{"公司":["爱美客","115","118"],"时间":["前三季度","173","177"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"归母净利润2.90亿元","content_offset":["199","210"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.90亿元","204","210"],"indicator_element":{"公司":["爱美客","115","118"],"时间":["前三季度","173","177"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"同比增加31.83%","content_offset":["211","221"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["31.83%","215","221"],"indicator_element":{"公司":["爱美客","115","118"],"时间":["前三季度","173","177"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"扣非后归母净利润2.80亿元","content_offset":["222","236"],"indicators":[{"indicator_name":"扣非后归母净利润","indicator_value":["2.80亿元","230","236"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","173","177"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"同比增加29.91%","content_offset":["237","247"],"indicators":[{"indicator_name":"扣非后归母净利润同比","indicator_value":["29.91%","241","247"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","173","177"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"公司Q3单季度实现营收2.23亿元","content_offset":["273","290"],"indicators":[{"indicator_name":"营业收入","indicator_value":["2.23亿元","284","290"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["Q3单季度","275","280"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"同比增长43.18%","content_offset":["291","301"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["43.18%","295","301"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["Q3单季度","264","269"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"实现归母净利润1.43亿元","content_offset":["302","315"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["1.43亿元","309","315"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["Q3单季度","264","269"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"同比增长55.97%","content_offset":["316","326"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["55.97%","320","326"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["Q3单季度","264","269"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"相比于上半年收入端0.72%的增速和归母净利润端14.59%的增速，Q3单季度提速加快","content_offset":["327","370"],"indicators":[{"indicator_name":"收入同比","indicator_value":["0.72%","336","341"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["上半年","330","333"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"相比于上半年收入端0.72%的增速和归母净利润端14.59%的增速，Q3单季度提速加快","content_offset":["327","370"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["14.59%","351","357"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["上半年","330","333"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"前三季度销售毛利率达69.41%（+5.73pct）","content_offset":["556","582"],"indicators":[{"indicator_name":"毛利率","indicator_value":["69.41%","566","572"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","556","560"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"销售费用率9.05%（-2.61pct）","content_offset":["593","613"],"indicators":[{"indicator_name":"销售费用率","indicator_value":["9.05%","598","603"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","556","560"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"管理费用率5.74%（-3.28pct）","content_offset":["614","634"],"indicators":[{"indicator_name":"管理费用率","indicator_value":["5.74%","619","624"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","556","560"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"研发费用率7.12%（-0.69pct","content_offset":["635","654"],"indicators":[{"indicator_name":"研发费用率","indicator_value":["7.12%","640","645"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","556","560"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"公司前三季度净利率达62.53%，同比提升6.84pct，环比H1提升","content_offset":["668","703"],"indicators":[{"indicator_name":"净利率","indicator_value":["62.53%","678","684"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","670","674"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"公司净利率稳步提升，经营性现金流2.59亿元","content_offset":["704","726"],"indicators":[{"indicator_name":"经营性现金流","indicator_value":["2.59亿元","720","726"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","670","674"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"同比提升20.47%","content_offset":["727","737"],"indicators":[{"indicator_name":"经营性现金流同比","indicator_value":["20.47%","731","737"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["前三季度","670","674"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"环比H1提升125.22%","content_offset":["738","751"],"indicators":[{"indicator_name":"经营性现金流环比","indicator_value":["125.22%","744","751"],"indicator_element":{"公司":["爱美客","1749","1752"],"时间":["H1","740","742"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"我们预计公司20-22年营业收入为7.16亿元、9.64亿元和13.39亿元","content_offset":["842","880"],"indicators":[{"indicator_name":"营业收入","indicator_value":["7.16亿元","859","865"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"营业收入","indicator_value":["9.64亿元","866","872"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"营业收入","indicator_value":["13.39亿元","873","880"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"22","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"归母净利润为4.58亿元、6.30亿元和8.49亿元","content_offset":["881","907"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["4.58亿元","887","893"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"归母净利润","indicator_value":["6.30亿元","894","900"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"归母净利润","indicator_value":["8.49亿元","901","907"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"23","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"对应EPS分别为3.81元/股、5.24元/股、7.07元/股","content_offset":["908","939"],"indicators":[{"indicator_name":"EPS","indicator_value":["3.81元/股","916","923"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"EPS","indicator_value":["5.24元/股","924","931"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"EPS","indicator_value":["7.07元/股","932","939"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}}]},{"id":"24","source_document":"爱美客（300896）2020年三季报评论：医美旺季来袭，业绩高质提升.pdf","content":"对应PE129/94/70","content_offset":["940","953"],"indicators":[{"indicator_name":"估值","indicator_value":["","940","940"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"估值","indicator_value":["","940","940"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}},{"indicator_name":"估值","indicator_value":["","940","940"],"indicator_element":{"时间":["20-22年","848","854"],"公司":["爱美客","1749","1752"]},"indicator_supplement":{"属性":"预计"}}]}]}